HLA class I downregulation is associated with enhanced NK‐cell killing of melanoma cells with acquired drug resistance to BRAF inhibitors
Open Access
- 20 December 2015
- journal article
- research article
- Published by Wiley in European Journal of Immunology
- Vol. 46 (2) , 409-419
Abstract
The frequent development of drug resistance to targeted therapies in cancer patients has stimulated interest in strategies counteracting resistance. Combining immunotherapies with targeted therapies is one such strategy. In this context, we asked whether human NK cells can target melanoma cells that have acquired resistance to selective inhibitors targeting activating mutants of the B‐Raf kinase (BRAF inhibitors, BRAFi). We generated drug‐resistant cell variants in vitro from human BRAF‐mutant melanoma cell lines MEL‐HO, COLO‐38, SK‐MEL‐37, 1520 and from primary melanoma cells freshly isolated from two patients. All drug‐resistant cell variants remained susceptible to lysis by IL‐2‐activated NK cells; and two BRAFi‐resistant lines (BRAFi‐R) became significantly more susceptible to NK‐cell lysis than their parental lines. This was associated with significant HLA class I antigen downregulation and PD‐L1 upregulation on the drug‐resistant lines. Although blocking HLA class I enhanced the extent of lysis of both BRAFi‐R and parental cells to NK‐cell‐mediated lysis, antibody‐mediated inhibition of PD1–PD‐L1 interactions had no detectable effect. HLA class I antigen expression on BRAFi‐R melanoma variants thus appears to play a major role in their susceptibility to NK‐cell cytotoxicity. These findings suggest that NK‐cell‐based immunotherapy may be a viable approach to treat melanoma patients with acquired resistance to BRAF inhibitors.Keywords
Funding Information
- UICC International Cancer Technology Transfer Fellowship and Italian Ministry of Health (CO-2011-02348049)
This publication has 50 references indexed in Scilit:
- CTLA-4 Is Expressed by Activated Mouse NK Cells and Inhibits NK Cell IFN-γ Production in Response to Mature Dendritic CellsThe Journal of Immunology, 2014
- Clinical utility of natural killer cells in cancer therapy and transplantationSeminars in Immunology, 2014
- Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyondEuropean Journal of Cancer, 2013
- Natural killer cell deficiencyJournal of Allergy and Clinical Immunology, 2013
- Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic MelanomaJournal of Clinical Oncology, 2013
- Vemurafenib reverses immunosuppression by myeloid derived suppressor cellsInternational Journal of Cancer, 2013
- The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K InhibitionClinical Cancer Research, 2013
- Pharmacological activation of p53 triggers anticancer innate immune response through induction of ULBP2Cell Cycle, 2011
- Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte FunctionCancer Research, 2010
- Mutations of the BRAF gene in human cancerNature, 2002